Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Possible effects of sarcopenia include decreased muscle strength, problems with mobility, frailty, weak bones, falls and fractures, decreased activity levels, diabetes, middle-age weight gain, and a loss of physical function and independence.  Learn more about sarcopenia and check out the Alliance-led Aging in Motion (AIM) Coalition that is working towards greater levels of research and innovation to develop treatments for sarcopenia.

Press Room

AIM Coalition Meeting Spotlights Sarcopenia Research Advances

Author: Noel Lloyd

Date: December 2nd, 2016

The Aging in Motion (AIM) Coalition hosted its second annual meeting with U.S. Food and Drug Administration (FDA) leaders and leading scientists, industry representatives, and advocates to discuss developments and advances in clinical research and treatment of sarcopenia in Bethesda, Md.


Update on Patient-Focused Drug Development Meeting on Sarcopenia

Author: Noel Lloyd

Date: April 20th, 2017

On April 6, the U.S. Food and Drug Administration held a public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when selecting a treatment.”

Join FDA's PFDD Meeting on Sarcopenia, April 6

Author: Breanna Bishop

Date: March 27th, 2017

The U.S. Food and Drug Administration is seeking people with sarcopenia to share their comments at a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia on April 6, from 1 p.m. to 5 p.m. EST. 


Patient Perspectives on Sarcopenia Sought by the FDA

Author: Noel Lloyd

Date: February 2nd, 2017

If you or a loved one has sarcopenia or if you want to understand more about how sarcopenia could impact you, the U.S. Food and Drug Administration wants to hear from you.

AIM Coalition's Webinar on ICD-10 for Sarcopenia Now Available

Author: Breanna Bishop

Date: January 26th, 2017

The Aging in Motion (AIM) Coalition recently hosted a webinar about the ICD-10 code for sarcopenia, titled "An ICD-10 Code for Sarcopenia: Implications for Diagnosis and Clinical Practice." An archived video of the webinar is now available. 

Webinar on an ICD-10 Code for Sarcopenia/January 24

Author: Breanna Bishop

Date: January 12th, 2017

In 2016, the Aging in Motion Coalition’s (AIM) proposal to establish an ICD-10-CM code for sarcopenia was accepted by the Centers for the Disease Control and Prevention. To provide additional insight into the process and its importance, AIM will be hosting a one-hour webinar on January 24, 2017.

AIM Coalition Held Second Annual Meeting

Author: Breanna Bishop

Date: December 15th, 2016

On December 2, the Aging in Motion (AIM) Coalition hosted its second annual meeting in Bethesda, Md., to discuss developments and advances in clinical research and treatment of sarcopenia.

We Bring People and Organizations Together to Advance Science

Author: Noel Lloyd

Date: May 13th, 2016

A major way the Alliance advances science is through building coalitions of diverse organizations and individuals to bring visibility and support to health research, with the ultimate goal of improving the healthy length and quality of life for everyone. Learn more. 

Good News about Sarcopenia from the AIM Coalition

Author: Noel Lloyd

Date: April 27th, 2016

Today, the Aging in Motion Coalition made a major announcement: The Centers for Disease Control and Prevention (CDC) has established an ICD-10-CM code for sarcopenia.

Expert Webinar on Frailty This Thursday

Author: Noel Lloyd

Date: April 19th, 2016

This Thursday, April 21, at 10 a.m. ET, the Aging in Motion Coalition holds a free expert webinar on frailty with featured speaker Francesca Cerreta, senior scientific officer, ‎European Medicines Agency (EMA).

Alliance's Bens to Participate in Symposium on Frailty

Author: Noel Lloyd

Date: March 29th, 2016

On April 7, the Alliance's Vice President of Public Policy Cynthia Bens will participate in a symposium titled "Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target" at the 28th Annual EuroMeeting in Hamburg, Germany.

Expert Robert Fielding on the Latest in Sarcopenia Research

Author: Noel Lloyd

Date: June 30th, 2015

To help you learn more about what's been going on in the sarcopenia research space, we are linking you to an interview with Roger A. Fielding, Ph.D.


Muscle Loss and Aging: Combatting Sarcopenia and Lost Independence

Date: February 1st, 2013

Typically, our muscles grow larger and stronger as we age. That is, until about the time we celebrate our 30th birthdays. That’s when most of us start down the other side of the hill and begin to gradually lose our muscle mass, strength, and function. While it’s usually not very noticeable in our 30s and 40s, the loss increases exponentially with age and tends to accelerate between the ages of 65 and 80.